A Day-74 letter has been issued by the FDA, confirming that the PDUFA target date for the marketing approval decision on the 3-month formulation of leuprolide mesylate given as a 21-mg variation for the treatment of adult patients with advanced prostate cancer is set for August 29, 2025.1...
The present review explored the current studies on the relevance of microbiota to Pca progression and treatment to provide direction for future microbiome-Pca research. Due to the complexity of the potential interconnections between Pca and the microbiota, further investigation is critical....
Treatment options for prostate cancer range from surgery and radiation to endocrine manipulation and chemotherapy. Choice of treatment is dependent on the stage of the disease and cost-benefit ratio, costs being assessed in both medical and economic terms. The evaluation of chemotherapy in prostatic ...
Prostate Cancer and Prostatic Diseases, covering all aspects of prostatic diseases, in particular prostate cancer. The journal is of interest to surgeons, oncologists, clinicians, and researchers involved in disease of the prostate.
Dr. Schwen on focal therapies for prostate cancer Speaking of Urology: Liquid biopsy in prostate cancer Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer Dr. Laviana on decisional regret after prostate cancer treatment Study finds lack of Black and Latinx representation in on...
prostate; however, this depends on the extent and location of the cancer. The urethra is then re-anastomosed to the bladder, and the incisions are closed. The prostate and seminal vesicles are sent to pathology to be analyzed, and we will review that report with you at your follow up ...
Selection of treatment for a patient with prostate cancer is often based on age and life expectancy. However, life expectancy estimates are often calculated solely on the basis of chronological age, overlooking comorbid conditions and their severity, whi
(HoxB13) have a higher-than-average risk of developing prostate cancer. In a systematic review and meta-analysis, the investigators noted that in these men with the HoxB13 mutation, the risk of prostate cancer is also affected by a family history of prostate cancer and the year of their ...
(HoxB13) have a higher-than-average risk of developing prostate cancer. In a systematic review and meta-analysis, the investigators noted that in these men with the HoxB13 mutation, the risk of prostate cancer is also affected by a family history of prostate cancer and the year of their ...
Phanes Therapeutics, Inc. announced that the FDA granted Fast Track designation to PT217 for the treatment of patients with metastatic de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). This is the second Fast Track Designation granted to PT217 by the FDA. E...